PMGC Holdings Inc.
ELABEarnings History
| Report Date | EPS Actual | EPS Est. | Revenue Actual | Revenue Est. |
|---|---|---|---|---|
| Aug 14, 2026 | $-6.10 | — | $1.3M | — |
| May 14, 2026 | $-11.21 | — | $682.0K | — |
| Mar 26, 2026 | $-5.19 | — | $304.1K | — |
| Nov 14, 2025 | $-1.19 | — | $285.9K | — |
| Aug 12, 2025 | $-38.63 | — | — | — |
| May 14, 2025 | $-243.56 | — | — | — |
| Apr 4, 2025 | $-321.96 | — | -$1.7M | — |
| Nov 13, 2024 | $-82.28 | — | $527.5K | — |
News
Study identifies preliminary lean-mass finding at the highest EL-32 dose while informing future preclinical development strategy Results advance NorthStrive Biosciences' engineered probiotic platform targeting muscle preservation for patients on GLP-1 weight loss treatments NEWPORT BEACH, Calif., Nov. 05, 2026 (GLOBE NEWSWIRE) -- PMGC Holdings Inc. (Nasdaq: ELAB) (“PMGC” or the “Company”) today announced the completion of a preclinical study evaluating EL-32, an engineered probiotic candidate be…
Adoption of NorthStrive® brand marks and DBA registration establishes a unified identify across PMGC's public holding company structure, with a formal legal name change expected within six months Adoption of NorthStrive® brand marks and DBA registration establishes a unified identify across PMGC's public holding company structure, with a formal legal name change expected within six months
PMGC's first sponsored SPAC adds a public-market acquisition vehicle to the holding company, targeting aerospace and defense, industrial technology, and critical supply chain manufacturers Sponsor position of approximately 2.7 million shares, or roughly 21.4% of NorthStrive Acquisition Corp I.'s Class A shares on an as-converted basis, aligns PMGC with value created through a future business combination NEWPORT BEACH, Calif.
Engagement of a leading global contract research organization strengthens the analytical foundation supporting EL-22 and EL-32 as the programs advance toward an IND-enabling development framework Builds on NorthStrive Biosciences' expanding manufacturing and characterization capabilities behind its engineered probiotic platform targeting muscle preservation, including for patients on GLP-1 weight loss treatments NEWPORT BEACH, Calif., Sept. 29, 2026 (GLOBE NEWSWIRE) -- PMGC Holdings Inc. (Nasdaq…
PMGC Holdings Inc. (Nasdaq: ELAB) Secures Five-Year Royalty Stream from Elevai Skincare Sale Under Executed Payment Agreement with Longevity Health Holdin
NorthStrive Biosciences Expands AI-Driven Drug Discovery Program with Yuva Biosciences, Advancing Four Novel AI-Discovered Compounds Toward Lead Nomination
PMGC Holdings Terminates Previously Announced Acquisition LOI Following Due Diligence Review; Reaffirms Disciplined M&A Strategy and Expands Investment Acr
PMGC Holdings Announces Term Sheet with Orbit2Orbit for NorthStrive Biosciences to Launch a Spaceflight Study of Its Myostatin and Activin A Assets, EL-22
NorthStrive Biosciences Announces The Filing of Two U.S. Patent Applications Targeting Microgravity-Induced Muscle Loss During Long-Duration Spaceflight
NEWPORT BEACH, Calif., Aug. 19, 2026 (GLOBE NEWSWIRE) -- PMGC Holdings Inc. (NASDAQ: ELAB) (“PMGC” or the “Company”) today announced that it will effect a 1-for-10 reverse stock split (the “Split”) of its issued and outstanding and authorized common stock, par value $0.0001 per share (“Common Stock”), effective at 12:00 am, Eastern time, on August 21, 2026.
PMGC Holdings Inc. [NASDAQ: ELAB] Reports Q2 2026 Results and Files Form 10-Q; Total Assets Reach $36.6 Million, Up 184% from Year-End 2025 and 290% Year-o